There are no Focus articles on MRNA.
There are no Transcripts on MRNA.
Marketwire (Wed, 7:30AM)
Marketwire (May 28, 2014)
Wed, Apr. 2, 9:26 AM
- Pico caps Rosetta Genomics (ROSG) and Marina Biotech (MRNA) establish a strategic collaboration to identify and develop microRNA-based products targeting neuromuscular diseases and dystrophies.
- Initial focus will be Becker and Duchenne muscular dystrophies and myotonic dystrophy.
- Rosetta will identify microRNAs associated with the diseases and, if correlative, will develop the diagnostic products. Marina will develop the therapeutics.
Mon, Mar. 31, 12:47 PM
Tue, Mar. 11, 12:47 PM
Wed, Feb. 26, 12:46 PM
Mon, Feb. 24, 12:48 PM
MRNA vs. ETF Alternatives
Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference and messenger RNA translational blocking.
Other News & PR